Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Summit Therapeutics (SMMT) with a Neutral rating and $21 price target The firm believes investor expectations for ivonescimab are too high. Summit is perceived as having the next Keytruda and as being a takeover candidate, but there is uncertainty around the reproducibility of the China datasets and lack of overall survival benefit seen to date, the analyst tells investors in a research note. As such, Piper prefers to wait for a better entry point.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with a Neutral at Piper Sandler
- Summit Therapeutics’ Promising Advancements in Cancer Treatment Drive Buy Rating
- Positive Outlook for Summit Therapeutics: Buy Rating Supported by Financial Stability and Strategic Developments
- Summit going concern language ‘non-issue,’ says Citi
- Summit Therapeutics notes ‘doubt’ about ability to continue as ‘going concern’